Deaths, ac­cu­sa­tions of in­sid­er trad­ing and an ear­ly warn­ing from Boehringer stir Han­mi con­tro­ver­sy

Con­tro­ver­sy over a lethal can­cer drug de­vel­oped by Han­mi and Boehringer In­gel­heim con­tin­ues to bub­ble up in Ko­rea.

In re­cent days a mem­ber of the op­po­si­tion Min­joo par­ty — Rep. Jung Choun-sook — cir­cu­lat­ed a let­ter from Boehringer In­gel­heim dat­ing back to Au­gust 23rd stat­ing that they were halt­ing en­roll­ment and stud­ies of ol­mu­tinib at the rec­om­men­da­tion of the Da­ta Mon­i­tor­ing Com­mit­tee, ac­cord­ing to a re­port in the Ko­rea Her­ald. And he ac­cused the coun­try’s food and drug safe­ty min­istry of al­low­ing tri­als to con­tin­ue even af­ter the dan­gers be­came ap­par­ent.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER